secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001867096-23-000066
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Q1 revenue $33.2M (+50% YoY); reaffirms 2023 guidance
-----------------------------------------------------------

- Total revenue $33.2M vs $22.1M in Q1 2022; Gvoke net revenue $15.0M (+21%), Keveyis $12.8M (+37%), Recorlev $4.5M.
- Net loss $16.8M ($0.12 per share); cash & investments $95.1M at March 31, 2023.
- 2023 guidance: revenue $135M-$165M; cash from ops ($57M)-($77M); year-end cash $45M-$65M.
- Announced XeriJect collaboration with Regeneron for two undisclosed monoclonal antibodies.
- Appointed Ricki Fairley to Board of Directors, increasing board to nine members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/0001867096-23-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/xers-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer